Clinical Trials Browser

Phase 2 × Bevacizumab × Clear all

NCT03526432 2026-06-05

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03937830 2026-06-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07059845 2026-06-04

FLORENZA

Phase 2 Recruiting

Ovarian Neoplasms

NCT02519348 2026-06-03

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03141684 2026-06-03

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Phase 2 Active not recruiting

63 enrolled 1 FDA

Sarcoma, Alveolar Soft Part

NCT03587311 2026-06-03

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Endometrioid Adenocarcinoma

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05211323 2026-06-03

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Liver Neoplasms

NCT05523440 2026-06-03

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

9 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Phase 2 Not yet recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07623577 2026-06-03

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT04954339 2026-06-02

DYNAMIC

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06820463 2026-06-02

AndroMETa-CRC

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07024784 2026-06-02

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT07621497 2026-06-02

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05231122 2026-06-01

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06096779 2026-06-01

Kirros

Phase 2 Recruiting

Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT06607458 2026-06-01

DEL-LIVER

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT02971501 2026-05-29

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

5 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase 2 Active not recruiting

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT06405061 2026-05-29

Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Phase 2 Suspended

Gastrointestinal

Carcinoma, Hepatocellular

NCT06465563 2026-05-29

SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Phase 2 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06890338 2026-05-29

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT05620771 2026-05-26

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07111546 2026-05-26

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumour

NCT02350530 2026-05-22

FORBES

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06955169 2026-05-22

MOMENTUM-1

Phase 2 Suspended

Meningioma

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07359456 2026-05-19

COLIBRI-GI

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05871021 2026-05-18

PRIDE

Phase 2 Recruiting

Glioblastoma

NCT06083844 2026-05-18

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2 Recruiting

Ovarian Neoplasms

NCT06783647 2026-05-18

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumour

NCT06948448 2026-05-18

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07012798 2026-05-13

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02308527 2026-05-12

BEACON

Phase 2 Completed

Neuroblastoma

NCT04042558 2026-05-12

GFPC 06-2018

Phase 2 Completed

150 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT07448922 2026-05-12

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Phase 2 Recruiting

Advanced Gynecological Malignancies

NCT06271837 2026-05-11

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Active not recruiting

Breast Neoplasms

NCT06792695 2026-05-11

CANTOR

Phase 2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Phase 2 Completed

19 enrolled 10 charts

DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT04374305 2026-05-06

INTUITT-NF2

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT06023862 2026-05-06

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT07446322 2026-05-05

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Ras-mutated Metastatic Colorectal Cancer

NCT07503756 2026-05-05

JS212 Combination Therapies in Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05491811 2026-05-04

EAGLE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07562490 2026-05-01

CLEAR-04

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07559760 2026-04-30

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms